CD8A and neoplasm: Compared to PBS, H-CD8+ T and ALDHlow-T, treatment with the ALDHhigh-T cells resulted in more significant anti-tumor immunity, which was evident by its inhibition of subcutaneous tumor growth and the prolonged overall survival.